Oxcarbazepine: Difference between revisions

(contraindications)
(serious adverse effects)
Line 76: Line 76:
==Adverse Reactions==
==Adverse Reactions==
===Serious===
===Serious===
*hyponatremia
*anaphylaxis
*angioedema
*drug rxn w/ eosinophilia and systemic sx
*Stevens-Johnson syndrome
*toxic epidermal necrolysis
*erythema multiforme
*acute generalized exanthematous pustulosis
*suicidality
*leukopenia
*thrombocytopenia
*pancytopenia
*agranulocytosis
*aplastic anemia
*pancreatitis
*withdrawal seizures if abrupt D/C
*withdrawal sx if abrupt D/C


===Common===
===Common===

Revision as of 01:36, 11 February 2016

Administration

  • Type: anti epileptic
  • Dosage Forms: 150,300,600; 300/5 mL
  • Routes of Administration: PO
  • Common Trade Names: Trileptal

Adult Dosing

Partial seizures

  • adjunct tx: Dose: 600 mg PO bid; Start: 300 mg PO bid, incr. by up to 600 mg/day qwk; Max: 2400 mg/day;
  • conversion to monotherapy: Dose: 1200 mg PO bid; Start: 300 mg PO bid, incr. by up to 600 mg/day qwk; Max: 2400 mg/day; D/C concomitant anticonvulsants over 3-6wk; taper dose gradually to D/C
  • initial monotherapy: Dose: 600 mg PO bid; Start: 300 mg PO bid, incr. by 300 mg/day q3 days; Max: 2400 mg/day

Trigeminal neuralgia

  • 450-1200 mg PO bid
  • Start: 300 mg PO bid, may incr. by 600 mg/day qwk

Bipolar disorder

  • 600-1200 mg PO bid
  • Start: 300 mg PO bid, incr. by 300 mg/day q3 days or by 600 mg/day qwk

Pediatric Dosing

Partial seizures

adjunct therapy

  • 2-3 yo
    • Dose: 60 mg/kg/day PO divided bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, incr. dose over 2-4wk; Max: 60 mg/kg/day
    • may start 16-20 mg/kg/day PO divided bid in pts <20 kg
  • 4-16 yo, 20-29 kg
    • Dose: 600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, incr. to target dose over 2wk
  • 4-16 yo, >39 kg
    • Dose: 900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, incr. to target dose over 2wk

monotherapy

  • 4-16 yo, 20-24 kg
    • Dose: 300-450 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
    • D/C concomitant anticonvulsants over 3-6wk
  • 4-16 yo, 25-34 kg
    • Dose: 450-600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
    • D/C concomitant anticonvulsants over 3-6wk
  • 4-16 yo, 35-44 kg
    • Dose: 450-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
    • D/C concomitant anticonvulsants over 3-6wk
  • 4-16 yo, 45-49 kg
    • Dose: 600-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
    • D/C concomitant anticonvulsants over 3-6wk
  • 4-16 yo, 50-59 kg
    • Dose: 600-900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
    • D/C concomitant anticonvulsants over 3-6wk
  • 4-16 yo, 60-69 kg
    • Dose: 600-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
    • D/C concomitant anticonvulsants over 3-6wk
  • 4-16 yo, >70 kg
    • Dose: 750-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
    • D/C concomitant anticonvulsants over 3-6wk

Special Populations

Renal Dosing

  • Adult: CrCl <30: start 150 mg bid; HD/PD: no supplement; Info: titrate dose slowly until response
  • Pediatric: CrCl <30: decr. start dose 50%, max start dose 300 mg/24h; HD/PD: no supplement; Info: titrate dose slowly until response

Hepatic Dosing

  • Adult: mild-mod impairment: no adjustment; severe impairment: not defined
  • Pediatric: mild-mod impairment: no adjustment; severe impairment: not defined

Contraindications

  • Allergy to class/drug
  • HLA-B*1502 allele (tx-naive pts)
  • avoid abrupt withdrawal
  • caution if hypersens. to carbamazepine
  • caution in elderly pts
  • caution in pregnancy
  • caution if hyponatremia
  • caution if renal impairment
  • caution if depression or hx

Adverse Reactions

Serious

  • hyponatremia
  • anaphylaxis
  • angioedema
  • drug rxn w/ eosinophilia and systemic sx
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • erythema multiforme
  • acute generalized exanthematous pustulosis
  • suicidality
  • leukopenia
  • thrombocytopenia
  • pancytopenia
  • agranulocytosis
  • aplastic anemia
  • pancreatitis
  • withdrawal seizures if abrupt D/C
  • withdrawal sx if abrupt D/C

Common

Pharmacology

  • Half-life:
  • Metabolism:
  • Excretion:

Mechanism of Action

Comments

See Also

References